Financial Comparison: Biofrontera (BFRI) vs. Its Competitors

Biofrontera (NASDAQ:BFRI) is one of 894 publicly-traded companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its rivals? We will compare Biofrontera to related companies based on the strength of its profitability, analyst recommendations, institutional ownership, valuation, risk, dividends and earnings.

Insider & Institutional Ownership

10.1% of Biofrontera shares are owned by institutional investors. Comparatively, 32.5% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 8.1% of Biofrontera shares are owned by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

Analyst Ratings

This is a summary of current ratings and recommmendations for Biofrontera and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Biofrontera	1	1	1	0	2.00
Biofrontera Competitors	7820	13783	25794	1036	2.41

As a group, “Pharmaceuticals” companies have a potential upside of 25.04%. Given Biofrontera’s rivals stronger consensus rating and higher probable upside, analysts clearly believe Biofrontera has less favorable growth aspects than its rivals.

Profitability

This table compares Biofrontera and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Biofrontera	-13.78%	-145.81%	-31.30%
Biofrontera Competitors	-2,393.19%	-220.45%	-16.12%

Valuation and Earnings

This table compares Biofrontera and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Biofrontera	$41.71 million	-$10.54 million	-1.92
Biofrontera Competitors	$3.54 billion	$3.17 billion	553.79

Biofrontera’s rivals have higher revenue and earnings than Biofrontera. Biofrontera is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.

Risk and Volatility

Biofrontera has a beta of 0.88, indicating that its share price is 12% less volatile than the S&P 500. Comparatively, Biofrontera’s rivals have a beta of -0.05, indicating that their average share price is 105% less volatile than the S&P 500.

Summary

Biofrontera rivals beat Biofrontera on 10 of the 13 factors compared.

About Biofrontera

Biofrontera Inc. (NASDAQ:BFRI) is a specialty pharmaceutical company focused on developing and commercializing prescription dermatology products, with an emphasis on treatments for precancerous and cancerous skin conditions. The company primarily serves the U.S. dermatology market through a commercial organization that supports physicians and other healthcare providers. Biofrontera’s principal product is Ameluz (aminolevulinic acid hydrochloride) topical gel, a prescription medication used with photodynamic therapy to treat actinic keratoses.